The Supreme Court on Monday declined to hear multiple appeals, including challenges from pharmaceutical companies opposing Medicare drug price negotiations and a former congressman seeking to overturn his insider trading conviction.

The court rejected appeals from drugmakers who objected to negotiating Medicare drug prices with the federal government under Biden-era legislation. The pharmaceutical companies had challenged the constitutionality of the Medicare price negotiation program, which allows the government to directly negotiate lower prices for certain high-cost medications covered by the federal health insurance program.

Separately, the court declined to take up former Rep. Stephen Buyer's bid to overturn his insider trading conviction. The Indiana Republican was convicted in 2023 on four federal charges related to hundreds of thousands of dollars he earned by trading on inside information he acquired as a telecommunications industry consultant after leaving Congress. A federal appeals court had previously affirmed his conviction.

The court also turned away Eli Lilly's challenge to whistleblower law provisions, though specific details of that case were not immediately available. The Supreme Court's decisions not to hear these cases effectively allows the lower court rulings to stand.

The pharmaceutical industry's challenge to Medicare drug price negotiations represented a significant test of the government's authority to control healthcare costs through direct price negotiations. The rejection of these appeals allows the Biden administration's drug pricing initiatives to continue without further legal impediment from these particular challenges.